Debora Carpanese

489 total citations
24 papers, 354 citations indexed

About

Debora Carpanese is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Debora Carpanese has authored 24 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Immunology. Recurrent topics in Debora Carpanese's work include Radiopharmaceutical Chemistry and Applications (7 papers), CAR-T cell therapy research (5 papers) and Peptidase Inhibition and Analysis (5 papers). Debora Carpanese is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (7 papers), CAR-T cell therapy research (5 papers) and Peptidase Inhibition and Analysis (5 papers). Debora Carpanese collaborates with scholars based in Italy, Mexico and Germany. Debora Carpanese's co-authors include Antonio Rosato, Isabella Monia Montagner, Gaia Zuccolotto, Giulio Fracasso, Cristina Bolzati, Vito Barbieri, Laura Meléndez‐Alafort, Anna Tosi, Roberta Sommaggio and Lorenzo Nicolè and has published in prestigious journals such as Scientific Reports, International Journal of Molecular Sciences and Journal of Controlled Release.

In The Last Decade

Debora Carpanese

22 papers receiving 349 citations

Peers

Countries citing papers authored by Debora Carpanese

Since Specialization

Citations

This map shows the geographic impact of Debora Carpanese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debora Carpanese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debora Carpanese more than expected).

Fields of papers citing papers by Debora Carpanese

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debora Carpanese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debora Carpanese. The network helps show where Debora Carpanese may publish in the future.

Co-authorship network of co-authors of Debora Carpanese

This figure shows the co-authorship network connecting the top 25 collaborators of Debora Carpanese. A scholar is included among the top collaborators of Debora Carpanese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debora Carpanese. Debora Carpanese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	On the adjuvanticity of hyaluronan: The case of a SARS-CoV-2 vaccine 2025 ·Journal of Controlled Release ·(unknown), Bruno Martorelli Di Genova, (unknown), Alessandro Sinigaglia, (unknown), Luisa Barzon, Matteo Pagliari, (unknown), (unknown), (unknown), Ranieri Verin, Anna Tosi, Debora Carpanese, Roberta Sommaggio, Vito Barbieri, (unknown), Gaia Zuccolotto, Antonella Grigoletto, Gianfranco Pasut, Antonio Rosato	0
2	Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back 2024 ·Frontiers in Immunology ·Valentina Rossi, (unknown), (unknown), Debora Carpanese	4
3	Development and Characterization of 99mTc-scFvD2B as a Potential Radiopharmaceutical for SPECT Imaging of Prostate Cancer 2023 ·International Journal of Molecular Sciences ·Cristina Bolzati, (unknown), Guillermina Ferro‐Flores, (unknown), Blanca Ocampo‐García, Debora Carpanese, Cristina Marzano, Barbara Spolaore, Giulio Fracasso, Antonio Rosato, Laura Meléndez‐Alafort	0
4	Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC 2023 ·BMC Pharmacology and Toxicology ·(unknown), (unknown), (unknown), Vincenzo Calderone, Alma Martelli, (unknown), Debora Carpanese, Elena Berti, (unknown)	3
5	Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations 2023 ·International Journal of Pharmaceutics ·Debora Carpanese, Valentina Rossi, (unknown), Luigi Quintieri, (unknown), Gaia Zuccolotto, (unknown), (unknown), (unknown), Giorgia Miolo, (unknown), Nicola Realdon, (unknown), (unknown), (unknown), Antonio Rosato	5
6	Hyaluronan as an immunological adjuvant: a novel application for an ancient molecule 2023 ·Cellular and Molecular Immunology ·Debora Carpanese, (unknown), Antonio Rosato	5
7	A Method for Risk Assessment Evaluating the Safety, Stability and Efficacy in Clinical Practice of Anticancer Drug Preparations in the Centralized Compounding Unit of the Veneto Institute of Oncology-IRCCS 2023 ·Pharmaceutics ·(unknown), (unknown), (unknown), Nicola Realdon, Debora Carpanese, (unknown)	2
8	Impact of Different [Tc(N)PNP]-Scaffolds on the Biological Properties of the Small cRGDfK Peptide: Synthesis, In Vitro and In Vivo Evaluations 2022 ·Molecules ·(unknown), Debora Carpanese, Laura Meléndez‐Alafort, Laura De Nardo, Andrea Calderan, Barbara Biondi, Paolo Ruzza, Antonio Rosato, Cristina Bolzati	3
9	A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer 2022 ·Molecules ·(unknown), (unknown), Debora Carpanese, (unknown), Laura Meléndez‐Alafort, Cristina Bolzati	23
10	Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines 2021 ·Cellular and Molecular Immunology ·(unknown), Debora Carpanese, Antonella Grigoletto, Anna Tosi, (unknown), Gabriel Kristian Pedersen, Dennis Christensen, Laura Meléndez‐Alafort, Vito Barbieri, Paola De Benedictis, Gianfranco Pasut, Isabella Monia Montagner, Antonio Rosato	28
11	PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation” 2021 ·Frontiers in Oncology ·Gaia Zuccolotto, (unknown), Giulio Fracasso, Debora Carpanese, Isabella Monia Montagner, (unknown), Antonio Rosato	20
12	Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen 2020 ·Scientific Reports ·Debora Carpanese, Guillermina Ferro‐Flores, Blanca Ocampo‐García, Clara Santos‐Cuevas, (unknown), Mariangela Figini, Giulio Fracasso, Laura De Nardo, Cristina Bolzati, Antonio Rosato, Laura Meléndez‐Alafort	14
13	P06.06 Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells 2020 ·INFM-OAR (INFN Catania) ·Roberta Sommaggio, Elisa Cappuzzello, (unknown), (unknown), Anna Tosi, Debora Carpanese, Lorenzo Nicolè, Antonio Rosato	1
14	Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells 2020 ·OncoImmunology ·Roberta Sommaggio, Elisa Cappuzzello, (unknown), Anna Tosi, (unknown), Debora Carpanese, Lorenzo Nicolè, Antonio Rosato	35
15	Targeting prostate cancer with the anti-PSMA scFvD2B: a theranostic promise for nuclear medicine 2019 ·Clinical and Translational Imaging ·Debora Carpanese, (unknown), Laura Evangelista, (unknown)	2
16	[^99mTc][Tc(N)PNP43]-Labeled RGD Peptides As New Probes for a Selective Detection of αvβ₃ Integrin: Synthesis, Structure–Activity and Pharmacokinetic Studies 2018 ·Journal of Medicinal Chemistry ·Cristina Bolzati, (unknown), Debora Carpanese, Roberta Seraglia, Laura Meléndez‐Alafort, Antonio Rosato, Domenica Capasso, Michele Saviano, Annarita Del Gatto, Daniela Comegna, Laura Zaccaro	18
17	Melanoma targeting with [ 99m Tc(N)(PNP3)]-labeled α-melanocyte stimulating hormone peptide analogs: Effects of cyclization on the radiopharmaceutical properties 2016 ·Nuclear Medicine and Biology ·Davide Carta, (unknown), (unknown), Feng Gao, Wiebke Sihver, (unknown), Barbara Biondi, Paolo Ruzza, Fiorenzo Refosco, Debora Carpanese, Antonio Rosato, Cristina Bolzati	10
18	A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer 2016 ·Journal of Controlled Release ·Isabella Monia Montagner, Anna Merlo, Debora Carpanese, (unknown), Anna Mero, Antonella Grigoletto, Arianna Loregian, Davide Renier, Monica Campisi, Paola Zanovello, Gianfranco Pasut, Antonio Rosato	20
19	Folic Acid-Conjugated Europium Complexes as Luminescent Probes for Selective Targeting of Cancer Cells 2015 ·Journal of Medicinal Chemistry ·Silvio Quici, (unknown), Francesca Foschi, Lidia Armelao, Gregorio Bottaro, Roberta Seraglia, Cristina Bolzati, (unknown), Debora Carpanese, Antonio Rosato	36
20	A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts 2015 ·Oncotarget ·Anastasia De Luca, Dante Rotili, Debora Carpanese, (unknown), Laura Calderan, Manuel Scimeca, Antonello Mai, Elena Bonanno, Antonio Rosato, Cristina Geroni, Luigi Quintieri, Anna Maria Caccuri	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact